Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Sell
18
BBNX Quote, Financials, Valuation and Earnings
Last price:
$12.69
Seasonality move
:
--
Day range:
$12.26 - $12.81
52-week range:
$8.89 - $24.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.75x
Volume:
618.8K
Avg. volume:
495.2K
1-year change:
--
Market cap:
$548.9M
Revenue:
$65.1M
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingBeta Bionics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.56, Beta Bionics has an estimated upside of 86.06% from its current price of $12.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $12.66.
Fair Value
-
According to the consensus of 8 analysts, Beta Bionics has 86.06% upside to fair value with a price target of $23.56 per share.
BBNX vs. S&P 500
-
Over the past 5 trading days, Beta Bionics has underperformed the S&P 500 by -4.73% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Beta Bionics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Beta Bionics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Beta Bionics reported revenues of --.
Earnings Growth
-
Beta Bionics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Beta Bionics reported earnings per share of --.
Enterprise value:
317.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $12.9M | $17.6M | |
| Gross Profit | -- | -- | -- | $7.2M | $9M | |
| Operating Income | -- | -- | -- | -$9.5M | -$18.6M | |
| EBITDA | -- | -- | -- | -$8.9M | -$18M | |
| Diluted EPS | -- | -- | -- | -$0.41 | -$0.93 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $261.9M | |
| Total Assets | -- | -- | -- | -- | $338M | |
| Current Liabilities | -- | -- | -- | -- | $16.5M | |
| Total Liabilities | -- | -- | -- | -- | $24.3M | |
| Total Equity | -- | -- | -- | -- | $313.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$12.1M | -$20M | |
| Cash From Investing | -- | -- | -- | $7.6M | -$179.1M | |
| Cash From Financing | -- | -- | -- | $6K | $211.1M | |
| Free Cash Flow | -- | -- | -$95.9M | -$12.6M | -$20.3M | |
BBNX
Sector
Market Cap
$548.9M
--
Price % of 52-Week High
51.67%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$13.04
200-day SMA
Buy
Level
$0.00
Bollinger Bands (100)
Sell
Level
11.57 - 17.93
Chaikin Money Flow
Buy
Level
973.3K
20-day SMA
Sell
Level
$14.53
Relative Strength Index (RSI14)
Sell
Level
32.79
ADX Line
Sell
Level
35.72
Williams %R
Buy
Level
-88.3253
50-day SMA
Sell
Level
$15.49
MACD (12, 26)
Sell
Level
-1.01
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
428.6K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-12.0642)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (14.4233)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Stock Forecast FAQ
In the current month, BBNX has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BBNX average analyst price target in the past 3 months is $23.56.
-
Where Will Beta Bionics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Beta Bionics share price will rise to $23.56 per share over the next 12 months.
-
What Do Analysts Say About Beta Bionics?
Analysts are divided on their view about Beta Bionics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beta Bionics is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Beta Bionics's Price Target?
The price target for Beta Bionics over the next 1-year time period is forecast to be $23.56 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BBNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Beta Bionics is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BBNX?
You can purchase shares of Beta Bionics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beta Bionics shares.
-
What Is The Beta Bionics Share Price Today?
Beta Bionics was last trading at $12.69 per share. This represents the most recent stock quote for Beta Bionics. Yesterday, Beta Bionics closed at $12.66 per share.
-
How To Buy Beta Bionics Stock Online?
In order to purchase Beta Bionics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 8.43% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 0.39% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 14.41% over the past day.
